LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
Sponsor: Eli Lilly and Company
Boston, MA · +39 more sites
15 recruiting ulcerative colitis studies with a site in Boston, MA.
Sponsor: Eli Lilly and Company
Boston, MA · +39 more sites
Sponsor: Eli Lilly and Company
Boston, MA · Waltham, MA · +9 more sites
Sponsor: Massachusetts General Hospital
Boston, MA
Sponsor: Spyre Therapeutics, Inc.
Boston, MA · +25 more sites
Sponsor: National Cancer Institute (NCI)
Boston, MA · +49 more sites
Sponsor: Bristol-Myers Squibb
Boston, MA · Springfield, MA · Worcester, MA · +33 more sites
Sponsor: Sanofi
Boston, MA · Worcester, MA · +116 more sites
Sponsor: University of North Carolina, Chapel Hill
Boston, MA · +10 more sites
Sponsor: Pfizer
Boston, MA · +19 more sites
Sponsor: Takeda
Boston, MA · +21 more sites
Sponsor: Northwestern University
Boston, MA · +12 more sites
Sponsor: Massachusetts General Hospital
Boston, MA
Sponsor: Boston Children's Hospital
Boston, MA
Sponsor: Brigham and Women's Hospital
Boston, MA
Sponsor: Brigham and Women's Hospital
Boston, MA
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.